155 related articles for article (PubMed ID: 21282028)
1. Characterization of a liposome-based formulation of oxaliplatin using capillary electrophoresis: encapsulation and leakage.
Franzen U; Nguyen TT; Vermehren C; Gammelgaard B; Ostergaard J
J Pharm Biomed Anal; 2011 Apr; 55(1):16-22. PubMed ID: 21282028
[TBL] [Abstract][Full Text] [Related]
2. Investigation of a liposomal oxaliplatin drug formulation by capillary electrophoresis hyphenated to inductively coupled plasma mass spectrometry (CE-ICP-MS).
Nguyen TT; Østergaard J; Stürup S; Gammelgaard B
Anal Bioanal Chem; 2012 Feb; 402(6):2131-9. PubMed ID: 22245979
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical characterization of a PEGylated liposomal drug formulation using capillary electrophoresis.
Franzen U; Vermehren C; Jensen H; Østergaard J
Electrophoresis; 2011 Mar; 32(6-7):738-48. PubMed ID: 21365657
[TBL] [Abstract][Full Text] [Related]
4. Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS.
Nguyen TT; Ostergaard J; Stürup S; Gammelgaard B
Int J Pharm; 2013 Jun; 449(1-2):95-102. PubMed ID: 23583709
[TBL] [Abstract][Full Text] [Related]
5. Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS.
Nguyen TT; Østergaard J; Stürup S; Gammelgaard B
Anal Bioanal Chem; 2013 Feb; 405(6):1845-54. PubMed ID: 23052859
[TBL] [Abstract][Full Text] [Related]
6. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
7. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
8. Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration.
Chaudhury A; Das S; Lee RF; Tan KB; Ng WK; Tan RB; Chiu GN
Int J Pharm; 2012 Jul; 430(1-2):167-75. PubMed ID: 22537806
[TBL] [Abstract][Full Text] [Related]
9. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
[TBL] [Abstract][Full Text] [Related]
10. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
11. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
14. Preparation, Characterization, and Antitumor Activities of Miriplatin-Loaded Liposomes.
Liu S; Li Y; Wang X; Ma J; Zhang L; Xia G
J Pharm Sci; 2016 Jan; 105(1):78-87. PubMed ID: 26852842
[TBL] [Abstract][Full Text] [Related]
15. Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy.
Corvo ML; Mendo AS; Figueiredo S; Gaspar R; Larguinho M; Guedes da Silva MF; Baptista PV; Fernandes AR
Pharm Res; 2016 Jun; 33(6):1351-8. PubMed ID: 27033349
[TBL] [Abstract][Full Text] [Related]
16. Direct and simultaneous determination of intra-liposomal and external sulfate in liposomal doxorubicin formulations by capillary electrophoresis/inductively coupled plasma-tandem mass spectrometry (CE/ICP-MS/MS).
Ansar SM; Mudalige T
Int J Pharm; 2019 Apr; 561():283-288. PubMed ID: 30844422
[TBL] [Abstract][Full Text] [Related]
17. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
18. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
[TBL] [Abstract][Full Text] [Related]
19. Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116.
Tippayamontri T; Kotb R; Paquette B; Sanche L
Invest New Drugs; 2011 Dec; 29(6):1321-7. PubMed ID: 20658169
[TBL] [Abstract][Full Text] [Related]
20. Development of a liposomal formulation of the natural flavonoid fisetin.
Mignet N; Seguin J; Ramos Romano M; Brullé L; Touil YS; Scherman D; Bessodes M; Chabot GG
Int J Pharm; 2012 Feb; 423(1):69-76. PubMed ID: 21571054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
